{"sequenceId":"845366288509","id":"34207237269","language":"English","title":"Intec Pharma (NTEC) Earns Daily Media Impact Rating of 0.18","content":"Media stories about Intec Pharma (NASDAQ:NTEC) have been trending somewhat positive on Saturday, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Intec Pharma earned a news impact score of 0.18 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.4562504570043 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.   A number of equities research analysts have weighed in on NTEC shares. HC Wainwright started coverage on Intec Pharma in a research note on Monday, February 26th. They issued a “buy” rating for the company. LADENBURG THALM/SH SH started coverage on Intec Pharma in a research note on Wednesday, February 28th. They issued a “buy” rating for the company. Oppenheimer set a $15.00 price objective on Intec Pharma and gave the company a “buy” rating in a research note on Wednesday, March 7th. Zacks Investment Research cut Intec Pharma from a “hold” rating to a “sell” rating in a research note on Friday, March 16th. Finally, Maxim Group boosted their price objective on Intec Pharma from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Monday, March 26th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $12.25. Intec Pharma traded up $0.10, reaching $4.70, on Friday, according to MarketBeat.com. The stock had a trading volume of 117,343 shares, compared to its average volume of 178,670. Intec Pharma has a 12-month low of $4.35 and a 12-month high of $9.80. The stock has a market cap of $146.07 million, a P/E ratio of -2.85 and a beta of 1.32. Intec Pharma (NASDAQ:NTEC) last issued its quarterly earnings data on Tuesday, May 15th. The biotechnology company reported ($0.41) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.13). equities analysts predict that Intec Pharma will post -1.21 EPS for the current year.   Intec Pharma Company Profile  Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.","contentWithMarkup":"Media stories about Intec Pharma (NASDAQ:NTEC) have been trending somewhat positive on Saturday, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Intec Pharma earned a news impact score of 0.18 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.4562504570043 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.   A number of equities research analysts have weighed in on NTEC shares. HC Wainwright started coverage on Intec Pharma in a research note on Monday, February 26th. They issued a “buy” rating for the company. LADENBURG THALM/SH SH started coverage on Intec Pharma in a research note on Wednesday, February 28th. They issued a “buy” rating for the company. Oppenheimer set a $15.00 price objective on Intec Pharma and gave the company a “buy” rating in a research note on Wednesday, March 7th. Zacks Investment Research cut Intec Pharma from a “hold” rating to a “sell” rating in a research note on Friday, March 16th. Finally, Maxim Group boosted their price objective on Intec Pharma from $8.00 to $12.00 and gave the company a “buy” rating in a research note on Monday, March 26th. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $12.25. Intec Pharma traded up $0.10, reaching $4.70, on Friday, according to MarketBeat.com. The stock had a trading volume of 117,343 shares, compared to its average volume of 178,670. Intec Pharma has a 12-month low of $4.35 and a 12-month high of $9.80. The stock has a market cap of $146.07 million, a P/E ratio of -2.85 and a beta of 1.32. Intec Pharma (NASDAQ:NTEC) last issued its quarterly earnings data on Tuesday, May 15th. The biotechnology company reported ($0.41) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.13). equities analysts predict that Intec Pharma will post -1.21 EPS for the current year.   Intec Pharma Company Profile  Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.","tags":[],"publishedDate":"2018-06-02T17:54:46Z","harvestDate":"2018-06-02T21:55:14Z","estimatedPublishedDate":"2018-06-02T17:54:46Z","url":"http://ct.moreover.com/?a=34207237269&p=1u0&v=1&x=pT2GDk4wmFf79ductu3mzg","originalUrl":"https://www.thestockobserver.com/2018/06/02/intec-pharma-ntec-earns-daily-media-impact-rating-of-0-18.html","outboundUrls":["http://www.americanconsumernews.net/scripts/click.aspx?Zacks=1","https://www.marketbeat.com/"],"wordCount":"427","dataFormat":"text","duplicateGroupId":"34207237269","media":{"audio":[],"images":[],"video":[],"logo":[]},"publishingPlatform":{},"adultLanguage":"false","topics":[{"name":"Pharma industry news","group":"Industry"},{"name":"Finance latest","group":"Finance"}],"companies":[{"name":"Intec Pharma Ltd","symbol":"NTEC","exchange":"NAS","isin":"IL0011177958","titleCount":1,"contentCount":13,"primary":true},{"name":"Intec Pharma Ltd","symbol":"NTEC","exchange":"TAE","isin":"IL0011177958","titleCount":1,"contentCount":13,"primary":true}],"author":{"name":"Brenda Bartman","publishingPlatform":{}},"licenses":[{"name":"Publicly Available"}],"source":{"name":"Stock Observer.com","homeUrl":"https://www.thestockobserver.com","category":"Trade","editorialRank":"3","location":{"country":"United States","countryCode":"US","region":"Americas","subregion":"Northern America"},"feed":{"id":"627334761","name":"Stock Observer.com","mediaType":"News","tags":[],"language":"Unassigned","dataFormat":"text","rank":{"inboundLinkCount":"1"},"inWhiteList":"true","autoTopics":[],"editorialTopics":["Professional","Financials"],"genre":"General"}},"es_id":86994208}